Latest Medical Devices News

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

USCOM Limited has completed the sale of its subsidiary Uscom SNG Pte. Ltd, marking a cessation of its operating activities and leaving the company with minimal cash reserves.

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.

Atomo Diagnostics has secured a substantial A$416,000 order for its HIV Self-Test kits destined for an African country, marking its second Global Fund-backed contract this year and signalling growing global demand.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

CONNEQT Health has reported a remarkable surge in Pulse device sales, exceeding 200% growth quarter-on-quarter, while advancing its transition to a recurring revenue model through enterprise contracts and consumer subscriptions.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Osteopore Limited reported a 30% year-on-year revenue increase in Q4 CY25, overcoming a slowdown in South Korea, and secured a strategic five-year partnership with DKSH Malaysia to expand its dental product reach.